Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134273 · ClinicalTrials.gov registry record · Phase 1
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,260
- Enrollment target
NCT04134273 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 1,260 participants.
The verdict
NCT04134273, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,260 participants
- Enrollment target
Study Summary
This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.
Interventions
- DRUG Placebo
- DRUG Clindamycin
- DRUG CLPG Topical Gel 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,260 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04134273
The ClinicalTrials.gov registry entry for NCT04134273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04134273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04134273 about?
NCT04134273 is a clinical study titled "Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris". This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.
What is the current status of trial NCT04134273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,260 participants. The study started on 2019-03-20. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT04134273?
The interventions under investigation include: Placebo (DRUG), Clindamycin (DRUG), CLPG Topical Gel 1% (DRUG).
Who is sponsoring clinical trial NCT04134273?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.